Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

3 Carolina seniors win Rhodes scholarships
For the second time ever, the University of North Carolina has three Rhodes scholars in the same year. Seniors Rotimi Kukoyi and Gabrielle Moreau received...
Mon Nov 17, 2025

UNC expands support for military and student veterans with success center
UNC-Chapel Hill unveiled its expanded Military and Veteran Student Success Center this week, a move aimed at better supporting students who are vets and their...
Sun Nov 16, 2025

Get to know the trees on UNC's campus
We seek refuge from the hot sun underneath them, stop and take photos when they change colors in fall and marvel at their height. There...
Sun Nov 16, 2025

Archaeological digs at UNC's New East yield centuries-old relics
On a sunny morning in late April, a group of North Carolina faculty and students hunched down on the ground outside New East and sifted...
Wed Nov 12, 2025